Neuroimaging thought leader to enhance PET/MRI and dementia research impact through AI-powered tools
San Diego, CA – Cortechs.ai is proud to announce the appointment of Dr. Ana M. Franceschi, MD, PhD, to its Medical Advisory Board. A nationally recognized expert in molecular neuroimaging and hybrid brain imaging techniques, Dr. Franceschi brings an outstanding track record of translational research and clinical leadership in dementia-focused imaging. She currently serves as Associate Professor of Radiology, Director of Dementia Imaging, and Director of Molecular Neuroimaging at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Lenox Hill Hospital in New York, NY.
With over 20 years of clinical and research experience, Dr. Franceschi has dedicated her career to advancing neuroimaging approaches in Alzheimer’s disease and related neurocognitive disorders. She has been a user and advocate of NeuroQuant since 2017, further underscoring her commitment to integrating advanced imaging technologies into routine clinical practice.
“We are honored to welcome Dr. Franceschi to the Cortechs.ai Medical Advisory Board,” said Kyle Frye, Chief Executive Officer of Cortechs.ai. “We admire her shared passion for enhancing patient care through innovation and her insights will be invaluable as we expand our AI-powered solutions to address the complexities of neurodegenerative disease.”
By joining Cortechs.ai’s advisory board, Dr. Franceschi will help shape the future of AI-enhanced neuroimaging tools, contributing her expertise to ensure clinical relevance and alignment with emerging diagnostic standards.
Dr. Franceschi stated, “I’m excited to join Cortechs.ai’s Medical Advisory Board at such a pivotal moment in the evolution of neuroimaging. Integrating AI into routine clinical practice is no longer a future aspiration—it’s a present necessity. I look forward to contributing my clinical perspective to help drive impactful, real-world applications.”
With this appointment, Cortechs.ai continues to strengthen its commitment to integrating top-tier clinical expertise into its development process, ensuring that its tools support physicians and researchers in providing the best possible care for patients.
For more information about Cortechs.ai and its cutting-edge imaging solutions, visit www.cortechs.ai.
About Cortechs.ai
Cortechs.ai is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical device software that provides quantitative MR imaging analysis to assist clinicians in assessing neurodegeneration, as well as brain and prostate cancer. Cortechs.ai’s industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess brain and prostate health, including cancer evaluation. The company also offers FDA-cleared products for evaluating neurological disorders such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit www.cortechs.ai and follow us on Twitter, LinkedIn, and Facebook.
For more information, please contact:
___________
+1 858 459 9700
